cefepime hydrochloride / Generic mfg. - LARVOL DELTA

SHORTEN-II: Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis. (clinicaltrialsregister.eu) - P4 | N=306 | Recruiting | Sponsor: Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla | Not yet recruiting ➔ Recruiting

Enrollment open

Piperacillin-tazobactam resistance in Klebsiella pneumoniae is often associated with IS26-mediated blaSHV-1 amplification in a widespread Klebsiella-adapted plasmid. (PubMed, Antimicrob Agents Chemother) - "To elucidate these mechanisms, we analyzed K. pneumoniae clinical isolates resistant to TZP but susceptible to cefotaxime and cefepime. Among 53 isolates, 14 were further studied by MIC testing for TZP, amoxicillin-clavulanic acid (AMC), and ceftazidime (CAZ)...Analysis of a K. pneumoniae genome data set confirmed the frequent co-occurrence of this plasmid and the PTnSHV-L marker in strains with multiple blaSHV copies. These findings suggest the emergence of an epidemic plasmid adapted to K. pneumoniae and driving TZP resistance through blaSHV-1 amplification, underscoring the need for genomic surveillance to detect amplification-based resistance overlooked by standard phenotypic or PCR assays."

Journal • Infectious Disease • Pneumonia

PARA-UMBLICAL HERNIA PRESENTING IN A PERITONEAL DIALYSIS PATIENT WITH CONCEALED SECONDARY PERITONITIS (ISN-WCN 2026) - "Peritoneal dialysis fluid was cloudy with 9000 cells/ml, TLC with 95% neutrophilic predominance and culture were suggestive of pseudomonas aeruginosa.Results Patient was initiated on intraperitoneal antibiotics cefepime, vancomycin and amikacin .But following a week of treatment she still had abdominal pain and cloudiness of PD effluent remained. In patients on continuous ambulatory peritoneal dialysis abdominal pain and lump with refractory PD peritonitis is a red flag and shouldn't be ignored. Secondary PD peritonitis; however rare but could be an elephant in the room in continuous ambulatory peritoneal dialysis patients with abdominal lump."

Clinical • Chronic Kidney Disease • Gastroenterology • Nephrology • Renal Disease

KLEBSIELLA PNEUMONIAE URINARY TRACT INFECTION CAUSING A PYOGENIC LIVER ABSCESS: A CASE REPORT (ISN-WCN 2026) - "Empiric antibiotic therapy with intravenous Piperacillin-Tazobactam (4.5 grams every 8 hours) was initiated...Antibiotic therapy was subsequently adjusted to Cefepime (2 grams IV every 12 hours), and later to Ciprofloxacin (400 mg IV every 12 hours) based on susceptibility testing...However, our case report identified the urinary tract as an unusual source, suggesting that certain K. pneumoniae strains may colonize the urinary tract and spread hematogenously to the liver via the portal vein. This unique blood supply make lymphatic dissemination also possible."

Case report • Clinical • Cardiovascular • Gastrointestinal Disorder • Hepatology • Hypertension • Infectious Disease • Nephrology • Pneumonia

NOVEL INSIGHTS INTO PHARMACOKINETICS OF INTRAPERITONEAL CEFEPIME DURING AUTOMATED PERITONEAL DIALYSIS USING MONTE CARLO SIMULATIONS (ISN-WCN 2026) - "Systemic cefepime clearance was 3.04 L/h (2.36-3.72).For patients without peritonitis, Monte Carlo simulations indicate that 1 g/day IP is sufficient to achieve the target of %fT>MIC ≥ 50% target for a MIC of 4 mg/L in both plasma and dialysate without accumulation, while 2 g/day is needed for a MIC of 8 mg/L in over 90% of patients (Figure 3). To reach the 8 mg/L target, 1.5 g/day IP was predicted to be sufficient in PDAP.Download: Download high-res image (265KB)Download: Download full-size imageDownload: Download high-res image (233KB)Download: Download full-size imageDownload: Download high-res image (406KB)Download: Download full-size imageConclusion These Monte Carlo simulations demonstrate that a single short-dwell administration can achieve effective plasma and dialysate / IP cefepime concentrations in APD patients with PDAP."

PK/PD data • Infectious Disease

ADJUNCTIVE HEMOPERFUSION USING HA-330 IN A SEVERE LUPUS FLARE WITH LUPUS NEPHRITIS AND DIFFUSE ALVEOLAR HEMORRHAGE: A CASE REPORT (ISN-WCN 2026) - "Proteinuria (UPCR 1.01 g/g) and imaging revealed bilateral infiltrates.She was clinically diagnosed with a severe SLE flare involving Class III lupus nephritis, diffuse alveolar hemorrhage, and acute renal failure, on top of relapsed pulmonary tuberculosis with superimposed hospital-acquired pneumonia.Initial therapy included high-flow oxygen, broad-spectrum antibiotics (Aztreonam + Cefepime, renally adjusted), anti-TB regimen excluding rifampicin, hydroxychloroquine, cautious corticosteroids (pulse withheld for ocular concern), and electrolyte correction.Results Due to worsening hypoxemia, rising inflammatory markers, and evolving kidney injury, two sessions of hemodialysis with hemoperfusion (HD + HP) using HA-330 were performed as cytokine-modulating adjunct therapy. Targeted cytokine removal may hasten stabilization and facilitate safer immunosuppression. The coexistence of DAH, lupus nephritis, infection, and relapsed TB underscores management challenges in..."

Case report • Clinical • Acute Kidney Injury • Glomerulonephritis • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Infectious consequences of antimicrobial change from vancomycin-piperacillin/ tazobactam to vancomycin-cefepime in the prevention of AKI during orthotopic heart transplantation. (PubMed, BMC Infect Dis) - "Culture-positive infections within 30 days post-OHT were similar between patients receiving empiric intraoperative VPT and those receiving VC."

Journal • Acute Kidney Injury • Infectious Disease • Nephrology • Renal Disease • Transplantation

Comparative Efficacy and Safety of Carbapenems Versus Non-Carbapenem Antibiotics in AmpC-Producing Enterobacterales Infections: A Systematic Review and Meta-Analysis. (PubMed, Int J Infect Dis) - "While carbapenems remain effective for AmpC-producing infections, non-carbapenem alternatives offer comparable outcomes with fewer adverse events. These findings support IDSA guidance recommending agents such as cefepime when the MIC is ≤2 µg/mL and highlight the need for individualized, susceptibility-guided therapy."

Journal • Retrospective data • Infectious Disease

Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of integral-1 study (ESCMID Global 2026) - No abstract available

Clinical

Efficacy of third-generation cephalosporins and piperacillin ± tazobactam compared with cefepime and carbapenems for the treatment of urinary source bacteraemia due to wild-type AmpC-producing Enterobacterales: a multi-centre, propensity score-weighted study (ESCMID Global 2026) - No abstract available

Clinical • Late-breaking abstract

Rational engineering of the R2-loop region of the PDC β-lactamase reveals a major impact on resistance to cefepime and cefiderocol in Pseudomonas aeruginosa (ESCMID Global 2026) - No abstract available

The in vitro activity of aztreonam/nacubactam and cefepime/nacubactam against molecularly characterised Enterobacterales isolates including those with ceftazidime-avibactam and aztreonam/avibactam resistance mechanisms collected globally from 2021-2023 (ESCMID Global 2026) - No abstract available

Preclinical

Exploring carbapenem-sparing strategies: in vitro susceptibility analysis of temocillin and cefepime against Enterobacterales bloodstream isolates (ESCMID Global 2026) - No abstract available

Preclinical

Activity of the novel combination therapy cefepime/nacubactam against 17,220 clinical isolates of Enterobacterales collected worldwide during 2021-2024 (ESCMID Global 2026) - No abstract available

Clinical • Combination therapy

Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam compared with imipenem/cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis: integral-1, a double-blind, randomised phase III trial (ESCMID Global 2026) - No abstract available

Clinical • P3 data • Infectious Disease • Nephrology

Outcomes of cefepime/nacubactam and aztreonam/nacubactam in cUTI/AP patients with ESBL-producing bacteria enrolled into prospective phase III randomised clinical study (Integral-1) (ESCMID Global 2026) - No abstract available

Clinical • P3 data

Outcomes of cefepime/nacubactam and aztreonam/nacubactam for treatment of cUTI/AP patients with CRE: subgroup analysis of integral-1 study (ESCMID Global 2026) - No abstract available

Clinical

Probability of target attainment of cefepime/nacubactam and aztreonam/nacubactam for carbapenem-resistant Enterobacterales infections (ESCMID Global 2026) - No abstract available

Infectious Disease

Determination of the nonclinical PK/PD target value for nacubactam in a mouse thigh infection model using carbapenem-resistant Enterobacterales under co-administration of cefepime or aztreonam (ESCMID Global 2026) - No abstract available

PK/PD data • Preclinical • Infectious Disease

Population pharmacokinetic analysis of nacubactam, cefepime, and aztreonam and exposure–response analysis of efficacy results from phase III clinical trials (ESCMID Global 2026) - No abstract available

Clinical • P3 data • PK/PD data

In vivo activity of cefepime/sulbactam in the Galleria mellonella invertebrate infection model (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease

Efficacy and safety of cefepime/nacubactam and aztreonam/nacubactam vs best available therapy in adults with cUTI/AP, HABP/VABP, cIAI due to carbapenem resistant Enterobacterales: integral-2, single-blind, randomised phase III trial (ESCMID Global 2026) - No abstract available

Clinical • P3 data

Evaluation of Resistance Dynamics in Pseudomonas aeruginosa Isolated From ICUs of a Tertiary-Level Hospital in Eastern India: A Five-Year Study. (PubMed, Cureus) - "Overall AST patterns revealed the highest susceptibility to amikacin (56%, 523/942), followed by cefepime (53%, 471/891)...Trend analysis showed a decline in resistance to piperacillin/tazobactam, meropenem, imipenem, ciprofloxacin, and levofloxacin over the 2021-2025 period...This is concerning, as ICU patients are critically ill and infections caused by drug-resistant pathogens may have severe consequences. Continuous antimicrobial stewardship, strict infection control practices, and active surveillance are essential to prevent further escalation of resistance."

Journal • Infectious Disease • Pediatrics

Genetic and phenotypic characterization of the plasmid-encoded NDM-80 metallo-β-lactamase in Escherichia coli isolated from a pediatric patient. (PubMed, Front Microbiol) - "The results indicated that E. coli carrying bla NDM-80 showed significant resistance to all β-lactam antibiotics except for aztreonam, aztreonam-avibactam, and cefiderocol...Steady-state kinetic determinations revealed that NDM-80 likely had higher hydrolytic activity against imipenem, meropenem, cefepime, and cefiderocol than NDM-1. This study is the first to report on the emergence of the bla NDM-80 variant, shedding light on its functional mechanism. Our findings enrich the repertoire of NDM resistance genes and highlight the need for increased surveillance of pathogens harboring bla NDM variants."

Journal • Critical care • Pediatrics

SYN-004 Safety and Tolerability in Allo-HCT Subjects (clinicaltrials.gov) - P1/2 | N=36 | Active, not recruiting | Sponsor: Theriva Biologics, Inc. | Trial completion date: Dec 2026 ➔ Sep 2030 | Trial primary completion date: Dec 2025 ➔ Sep 2029

Trial completion date • Trial primary completion date • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation